Published in Gastroenterology on March 01, 2006
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol (2008) 3.34
Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther (2014) 3.32
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology (2013) 2.60
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Hepatitis B virus-induced oncogenesis. World J Gastroenterol (2007) 1.82
Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78
The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int (2008) 1.77
Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73
Viral hepatocarcinogenesis. Oncogene (2010) 1.73
Poor adherence to AASLD guidelines for chronic hepatitis B Management and treatment in a large academic medical center. Am J Gastroenterol (2014) 1.72
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis (2009) 1.52
Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Ethanol Extract from Ampelopsis sinica Root Exerts Anti-Hepatitis B Virus Activity via Inhibition of p53 Pathway In Vitro. Evid Based Complement Alternat Med (2011) 1.39
Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int (2007) 1.38
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol (2012) 1.27
Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect (2008) 1.22
The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis (2011) 1.17
A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One (2011) 1.16
Current management of hepatocellular carcinoma. World J Gastroenterol (2014) 1.14
Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int (2007) 1.13
HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int (2009) 1.13
Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat (2009) 1.10
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol (2014) 1.10
Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol (2006) 1.08
Management of hepatitis B in developing countries. World J Hepatol (2011) 1.08
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci (2010) 1.07
The economics of treating chronic hepatitis B in Asia. Hepatol Int (2008) 1.04
A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) (2011) 1.04
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci (2014) 1.02
Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J (2011) 1.01
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J (2011) 1.00
Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol (2012) 0.99
Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int (2007) 0.98
Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients. Ann Gastroenterol (2015) 0.98
The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int (2008) 0.98
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver (2011) 0.97
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother (2012) 0.97
Relationship between level of hepatitis B virus DNA and liver disease: a population-based study of hepatitis B e antigen-negative persons with hepatitis B. Clin Gastroenterol Hepatol (2013) 0.96
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol (2012) 0.96
Chronic hepatitis B in Asian women of childbearing age. Hepatol Int (2009) 0.95
Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer (2012) 0.95
Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci (2014) 0.95
Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol (2013) 0.94
Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol (2015) 0.93
Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci (2009) 0.93
Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers. World J Gastroenterol (2009) 0.93
Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy. Gut Liver (2015) 0.93
Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci (2011) 0.93
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
Update on hepatitis B virus infection. World J Gastroenterol (2014) 0.93
Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med (2010) 0.92
Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepat Mon (2013) 0.92
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol (2012) 0.91
Monitoring during and after antiviral therapy for hepatitis B. Hepatology (2009) 0.91
Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int (2008) 0.91
Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int (2007) 0.91
Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver (2010) 0.90
Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. Dig Dis Sci (2011) 0.90
Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol (2014) 0.90
Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol (2015) 0.89
Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One (2013) 0.89
SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol (2014) 0.89
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany. Dig Dis Sci (2015) 0.89
Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients. J Clin Immunol (2010) 0.88
Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health (2009) 0.88
Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. J Korean Med Sci (2010) 0.88
Histological changes in chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal. Dig Dis Sci (2009) 0.88
Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med (2014) 0.88
Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol (2014) 0.87
The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection. Virol J (2010) 0.87
Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int (2010) 0.87
Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One (2013) 0.87
Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med (2015) 0.87
DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol (2009) 0.87
Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus. J Virol (2007) 0.87
Strategies to eliminate HBV infection. Future Virol (2014) 0.87
Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. Gut Liver (2015) 0.86
Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig Dis Sci (2011) 0.86
Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol (2014) 0.86
Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int (2008) 0.86
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. Dig Dis Sci (2016) 0.86
Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci (2012) 0.85
Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One (2013) 0.85
Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One (2013) 0.85
Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol Hepatol (N Y) (2011) 0.85
Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults. World J Gastroenterol (2007) 0.85
Liver physiology and liver diseases in the elderly. World J Gastroenterol (2013) 0.84
Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution. PLoS One (2014) 0.84
The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat (2007) 0.84
HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. Eur J Clin Microbiol Infect Dis (2011) 0.84
Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst (2008) 0.83
Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients. BMC Infect Dis (2016) 0.83
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A (2008) 4.06
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
A novel 5-enolpyruvoylshikimate-3-phosphate (EPSP) synthase transgene for glyphosate resistance stimulates growth and fecundity in weedy rice (Oryza sativa) without herbicide. New Phytol (2013) 3.44
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis (2012) 3.22
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis (2003) 2.47
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA (2004) 2.39
The effects of chronic arsenic exposure from drinking water on the neurobehavioral development in adolescence. Neurotoxicology (2003) 2.29
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
C-reactive protein concentration as a significant correlate for metabolic syndrome: a Chinese population-based study. Endocrine (2012) 2.19
Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst (2011) 2.18
Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med (2010) 2.17
Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res (2007) 2.02
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology (2009) 1.95
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology (2010) 1.89
Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol (2002) 1.88
Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. Am J Epidemiol (2015) 1.87
Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke (2010) 1.82
Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology (2012) 1.81
Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst (2002) 1.79
Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation (2002) 1.78
Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology (2010) 1.78
Cancer trends in Taiwan. Jpn J Clin Oncol (2010) 1.73
Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology (2007) 1.70
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology (2010) 1.69
Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int (2009) 1.65
Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol (2005) 1.64
Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol (2003) 1.63
Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res (2006) 1.62
Optimal anthropometric factor cutoffs for hyperglycemia, hypertension and dyslipidemia for the Taiwanese population. Atherosclerosis (2009) 1.62
Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii: a matched case-control study in intensive care units. Diagn Microbiol Infect Dis (2008) 1.61
Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control (2010) 1.61
Use of arsenic-induced palmoplantar hyperkeratosis and skin cancers to predict risk of subsequent internal malignancy. Am J Epidemiol (2013) 1.61
Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc (2006) 1.60
Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 1.60
Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology (2011) 1.59
The mortality risks of smokers in Taiwan: Part I: cause-specific mortality. Prev Med (2004) 1.59
Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol (2011) 1.57
Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One (2011) 1.55
Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol Lett (2003) 1.50
A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol Appl Pharmacol (2006) 1.50
Application of penetration device (Tornus) for percutaneous coronary intervention in balloon uncrossable chronic total occlusion-procedure outcomes, complications, and predictors of device success. Catheter Cardiovasc Interv (2011) 1.49
Safety and efficacy of transradial vs transfemoral arterial primary coronary angioplasty for acute myocardial infarction: single-center experience. Circ J (2009) 1.49
Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer (2002) 1.48
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology (2013) 1.45